- A meta-analysis finds that the point prevalence of comorbid major depressive disorder (MDD) is 25% in patients with fibromyalgia (FM), using structured clinical interviews (SCI), the diagnostic gold standard.
- Lifetime prevalence of comorbid MDD is 65%.
- Calculating prevalence using patient-administered methods likely yields an overestimate of MDD comorbidity.
Why this matters
- Depression should be routinely screened for in all FM cases, using clinician-administered SCI or screening symptom scales (SSS).
- Meta-analysis of 11 studies (n>1000) after search of MEDLINE, EMBASE, CENTRAL, and PsychINFO.
- Inconsistency was assessed by heterogeneity.
- Funding: None.
- Using clinician-administered SCI:
- Pooled point prevalence of MDD was 25% (95% CI, 19%-31%).
- Pooled lifetime prevalence of MDD was 65% (95% CI, 59%-71%).
- Clinician-administered SSS:
- Pooled point prevalence of MDD was 23% (95% CI, 10%-41%).
- Patient-administered SSS:
- Pooled point prevalence was 45% (95% CI, 32%-59%).
- Low inconsistency was seen for clinician-administered point prevalence (I2=42.36%), and no inconsistency for clinician-administered lifetime prevalence (I2=0.00%); high inconsistency was seen for the patient-administered point prevalence (I2=92.13%).
- Classification of MDD and FM varied across studies.